ARTICLE | Clinical News

Achillion hits 52-week high on HCV data

November 11, 2014 3:12 AM UTC

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) gained $2.74 (27%) to $12.85 on Monday after reporting an SVR12 of 100% in an ongoing Phase II study of ACH-3102 to treat HCV genotype 1 at the American Association for the Study of Liver Diseases (AASLD) conference. Shares reached a 52-week high of $12.95 during the day.

All 12 treatment-naive patients receiving the combination of 50 mg of ACH-3012, a pan-genotypic second-generation HCV NS5A protein inhibitor, and 400 mg of Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) achieved SVR12. Nine had a baseline viral load substantially greater than six million IU/ml. There were no cases of on-treatment viral breakthrough or post-treatment viral relapses. Sovaldi, a nucleotide analog HC NS5B polymerase inhibitor, served as a proxy for ACH-3422, Achillion's HCV NS5B uridine nucleotide polymerase inhibitor. ...